Genor Biopharma Secures NMPA Approval for Lerociclib to Treat Advanced Breast Cancer
I'm PortAI, I can summarize articles.
Genor Biopharma Holdings Ltd. has received approval from the China National Medical Products Administration (NMPA) for its drug Lerociclib (GB491), a selective CDK4/6 inhibitor. This drug is intended for adult patients with HR+/HER2- locally advanced or metastatic breast cancer, to be used with an aromatase inhibitor or fulvestrant. This approval marks a significant achievement for Genor Biopharma and highlights its collaboration with G1 Therapeutics Inc.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments